Business Context and Reporting Period
This Form 6-K filing by MDxHealth SA, dated January 20, 2023, serves to furnish a press release and corrected financial information. The filing addresses unaudited interim condensed financial statements for the nine months ended September 30, 2022, and revised pro forma financial information related to the acquisition of the Oncotype DX GPS test.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references attached exhibits (99.2 and 99.3) containing the unaudited interim condensed financial statements and revised pro forma data. The document explicitly states that these exhibits reflect corrections to previously reported figures.
Material Changes and Corrections
- Financial Restatement: The Company identified cut-off errors in its previously reported financial information for the nine months ended September 30, 2022. These errors have been corrected in the attached financial statements.
- Pro Forma Adjustments: Revised unaudited combined pro forma condensed balance sheets and statements of operations regarding the Oncotype DX GPS acquisition have been filed, correcting data previously submitted on December 19, 2022.
- Internal Control Weakness: A material weakness in internal control over financial reporting was identified as of September 30, 2022. This weakness stemmed from ineffective design and operation of interim financial close and reporting controls, which failed to detect the aforementioned cut-off errors.
Outlook, Risks, and Management Commentary
Management is taking remediation actions, including engaging an outside IFRS consulting firm to assist with the interim closing process. However, the Company notes that these efforts may not be sufficient to prevent future material weaknesses.
Risks and Contingencies:
- Undetected material weaknesses could lead to future financial statement restatements and incur remediation costs.
- Inability to remediate the current weakness or identify future issues could erode investor confidence in the accuracy of reported financial information.
- Loss of investor confidence may negatively impact the trading price of the Company's ADSs.
Investor Verification Checklist
- Review Exhibit 99.2 for the corrected unaudited interim condensed financial statements for the nine months ended September 30, 2022.
- Examine Exhibit 99.3 for the revised pro forma financial information regarding the Oncotype DX GPS acquisition.
- Assess the specific nature of the "cut-off errors" corrected in the financial statements.
- Monitor the Company's progress in remediating the material weakness in internal controls over financial reporting.
- Verify the impact of the corrected financial data on the Company's liquidity and operational status compared to prior reports.